secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K/A
Filed at:   2026-08-04T11:01:21+00:00
Accession:  0001171843-26-005168
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst estimates $6.2-7.5M in severance costs for discovery program discontinuation
--------------------------------------------------------------------------------

- Plan to discontinue internal discovery programs and close Birmingham, AL facility announced June 29, 2026.
- One-time expenses of $6.2-7.5M for employee termination benefits and severance; $5.3-6.6M cash expenditures.
- Facility closure costs (contract/lease termination, asset impairment) not yet estimable; further filing expected.
- Restructuring part of strategic evolution to strengthen rare disease pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326005168/0001171843-26-005168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326005168/f8ka_080326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer